

01 FEB 13 PM 12:29

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name AstraZeneca Pharmaceuticals LP		ID No. 34975000
2. Address ☐ Check if different than previously reported 1800 Concord Pike, P.O. Box 15437		
3. Principal Place of Business (if different from line 2) City: Wilmington State/Zip (or Country): DE 19850-5437		
4. Contact Name Luke W. Mette	Telephone (302) 886-3690	E-mail (optional) ID No. 54073-12
7. Client Name ☒ Self	6. House ID # ID No. 34975000	

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☒

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ Termination Date _____

11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 ☐ \$10,000 or more ☐ \$ _____ (income (nearest \$20,000)) Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 ☐ \$10,000 or more ☒ \$ <u>320,000.00</u> (expenses (nearest \$20,000)) 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. ☒ Method A. Reporting amounts using LDA definitions only ☐ Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code ☐ Method C. Reporting amounts under section 162(e) of the Internal Revenue Code
--	---

Signature *Luke W. Mette*

Printed Name and Title Luke W. Mette, Attorney

LD-2 (REV. 6/98)

PAGE 1 of 4

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

H.R. 4461/S. 2536 (P.L. 106-387) - Agriculture, FDA and Related Agencies
Appropriations, FY 2001

Calls and visits to members to support adequate FDA funding levels, and to oppose
language and amendments to modify reimportation provisions.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
James P. Schlicht - Executive Director, Federal Govt. Affairs		☐
Stephen D. McMillan - Senior Manager, Federal Govt. Affairs		☐
Dyan McGrath - Senior Manager, Federal Govt. Affairs		☐
		☐
		☐
		☐
		☐
		☐

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date _____

Printed Name and Title Luke W. Mette, Attorney

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 4680 - Medicare Rx 2000 Act

S. 2807 - Medicare 2000 Act

S. 2836 - Medicare Rx Drug Discount and Security Act of 2000

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House of Representatives

U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Yes
James P. Schlicht - Executive Director		☐
Federal Govt. Affairs		
Stephen D. McMillan - Senior Manager,		☐
Federal Govt. Affairs		
Dyan McGrath - Senior Manager,		☐
Federal Govt. Affairs		
		☐
		☐
		☐
		☐
		☐
		☐

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date _____

Printed Name and Title Luke W. Mette, Attorney

Registrant Name AstraZeneca Pharmaceuticals, LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMH (one per page)

16. Specific lobbying issues

H.R. 4577/H.R. 5656 (P.L. 106-554) - Omnibus Consolidated Appropriations Act

Calls and visits regarding reimbursements of Medicare Part B-covered drugs, modifications to HCFA coding procedures, and a General Accounting Office study on average wholesale prices.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

U.S. House of Representatives

U.S. Senate


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
James P. Schlicht - Executive Director, Federal Govt. Affairs		☐
Stephen D. McMillan - Senior Manager, Federal Govt. Affairs		☐
Dyan McGrath - Senior Manager, Federal Govt. Affairs		☐
		☐
		☐
		☐
		☐
		☐

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature



Date

2/12/01

Printed Name and Title

Luke W. Merte, Attorney

Form LO 2 (Rev. 6/95)

Page 4 of 4